Development of medicated foams that combine incompatible hydrophilic and lipophilic drugs for psoriasis treatment
| Autor: | Žane Temova Rakuša, Janja Mirtič, Mirjam GosencaMatjaž, Foteini Papathanasiou, Julijana Kristl, Robert Roškar |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Drug
media_common.quotation_subject Pharmaceutical Science Viscoelastic Substances 02 engineering and technology Excipients Surface-Active Agents 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Humans Psoriasis Cholecalciferol media_common chemistry.chemical_classification Aqueous solution Chromatography Polymer 021001 nanoscience & nanotechnology chemistry Emulsion Emulsions lipids (amino acids peptides and proteins) Chemical stability Tocopheryl acetate 0210 nano-technology Salicylic acid |
| Zdroj: | International Journal of Pharmaceutics. 524:65-76 |
| ISSN: | 0378-5173 |
| DOI: | 10.1016/j.ijpharm.2017.03.061 |
| Popis: | The focus was on the development of medicated foam for incorporation of two incompatible active agents for psoriasis treatment; i.e., lipophilic cholecalciferol, and hydrophilic salicylic acid. Emphasis was given to formulation of a propellant-free foam, with sufficient foaming properties, physical and chemical stability, and low irritancy potential to maintain relevance for later translation into clinical practice. Various excipients and concentrations were examined to achieve suitable foam stability parameters, viscoelasticity, and bubble-size, which relate to foamability and spreadability. The major positive impact on these properties was through a combination of surfactants, and by inclusion of a viscosity-modifying polymer. Incorporation of the incompatible drugs was then examined, noting the instability of cholecalciferol in an acidic environment, with the design aim to separate the drug distributions among the different foam phases. Cholecalciferol was stabilized in the emulsion-based foam, with at least a 30-fold lower degradation rate constant compared to its aqueous solution. The composition of the emulsion-based foam itself protected cholecalciferol from degradation, as well as the addition of the radical-scavenging antioxidant tocopheryl acetate to the oil phase. With the patient in mind, the irritancy potential was also examined, which was below the set limit that defines a non-irritant dermal product. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect